Pfizer Extends RNA Drug Deal

January 5, 2010 | Pfizer is expanding Wyeth's 2009 partnershp with Santaris Pharma in a deal that could be worth more than $600 million. Pfizer will pay Santaris $14 million for up to 10 drug candidates designed to target RNA. Milestone payments and royalties would follow any approved drugs. Bloomberg